TABLE 1.
Conditioning regimen and results
| CP/TBI dose | N | TIa | ATG | Anti-CD154 | Spxb | Multilineage chimerism | Kidney graft survival (d) | Outcome (no. animals) | |
|---|---|---|---|---|---|---|---|---|---|
| A | CP 40 mg/kg×3 | 1 | + | + | + | − | 0/1 | 59 | ACRc (1) |
| B | CP 150 mg/kg×3 | 2 | + | + | + | − | 0/2 | 76, 1 | ACR (1), bleeding (1) |
| C | CP 50 mg/kg×4 | 5 | + | + | + | − | 4/5 | 175, 118, 82, 70, 5 | ACR (1), ACR+pyelonephritis (1), CHRd (1), PTLDe (1) Hemorrahagic cystitis (1) |
| D | CP 50 mg/kg×4 | 2 | + | + | − | − | 0/2 | 51, 11 | PTLD (1), infection (1) |
| E | TBI 1.5 Gy×1 | 1 | + | + | − | + | 0/1 | 56 | ACR |
| F | TBI 2.3 Gy×1 | 3 | + | + | − | + | 0/3 | 69, 59, 43 | ACR (3) |
| G | TBI 1.25 Gy×2 | 9 | + | + | − | + | 2/9 | 155, 145, 93, 93, 92, 90, 61, 50, 37 | ACR (7), urolithiasis (2) |
| Hf | TBI 1.5 Gy×2 | 13 | + | + | − | + | 11/13 | >3478, >2569, 834, 771, 405, 260, 198, 196, 137, 72, 44, 40, 37 | No rejection (7), ACR (3) |
| Ig | TBI 1.5 Gy×2 | 8 | + | + | + | − | 8/8 | >1710, >1167, 837, 755, 401, 373, 206, 58 | No rejection (4), ACR (1), CR (3) |
a
Thymic irradiation
b
Splenectomy
c
acute cellular rejection
d
chronic humoral rejection
e
Posttransplant lymphoproliferative disease
f
Kawai T et al. Transplantation 1999; 68: 1767–1775
g
Kawai T et al. Am J Transplant 2004; 4: 1391.